Holmes Julia S, Shevrin Matt, Goldman Beth, Share David
National Center for Health Statistics, Centers for Disease Control and Prevention, USA.
Med Care Res Rev. 2004 Dec;61(4):453-73. doi: 10.1177/1077558704269501.
Despite the widespread availability of evidence-based guidelines for treating hypertension, recent evidence suggests that physicians may not be prescribing first-line drugs for their patients with high blood pressure. Using administrative claims data from 1998 through 2000, this study investigates whether drug treatment provided to 6,736 hypertensives in a privately insured, non-HMO population follows practice guidelines. The authors also examine physician and patient-related factors associated with guideline adherence in a subset of patients with newly diagnosed hypertension. Among members with high blood pressure alone, only 38 percent were on a diuretic, while less than a third were prescribed a beta-blocker, the JNC VI recommended first-line antihypertensives for essential hypertension. Approximately half of individuals with high blood pressure and certain comorbidities received non-first-line interventions. Such findings indicate the need to reconsider how guidelines are communicated and shared with medical practitioners and patients, particularly in light of the drug industry's promotion of newer, more expensive drugs.
尽管有广泛可用的基于证据的高血压治疗指南,但最近的证据表明,医生可能并未为高血压患者开具一线药物。本研究利用1998年至2000年的行政索赔数据,调查了在一个私人保险的非健康维护组织(HMO)人群中,为6736名高血压患者提供的药物治疗是否遵循实践指南。作者还在一组新诊断高血压患者中,研究了与指南依从性相关的医生和患者相关因素。在仅患有高血压的成员中,只有38%的人使用利尿剂,而不到三分之一的人被开具β受体阻滞剂,这是美国国家联合委员会第六版(JNC VI)推荐的原发性高血压一线抗高血压药物。约一半患有高血压并伴有某些合并症的个体接受了非一线干预措施。这些发现表明,需要重新考虑如何与医生和患者沟通及分享指南,尤其是鉴于制药行业对更新、更昂贵药物的推广。